🍽️ (s)-(-)-atenolol,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Beta-Blocker Action: Atenolol is a selective beta-1 adrenergic receptor antagonist, meaning it specifically blocks the action of beta-1 adrenergic receptors. By inhibiting these receptors, atenolol reduces the effects of adrenaline and noradrenaline on the heart, leading to decreased heart rate and reduced force of contraction of the heart muscle.

  2. Antihypertensive Effects: (S)-(-)-atenolol is primarily used in the treatment of hypertension (high blood pressure). By decreasing heart rate and cardiac output, as well as reducing renin release from the kidneys, atenolol helps lower blood pressure and reduce the workload on the heart. This can help prevent complications associated with hypertension, such as stroke, heart attack, and kidney damage.

  3. Management of Angina Pectoris: Atenolol may also be prescribed for the management of angina pectoris, a condition characterized by chest pain or discomfort due to reduced blood flow to the heart muscle. By decreasing heart rate and myocardial oxygen demand, atenolol helps relieve anginal symptoms and improve exercise tolerance in individuals with stable angina.

  4. Antiarrhythmic Effects: Atenolol has antiarrhythmic properties and may be used in the treatment of certain types of cardiac arrhythmias, particularly supraventricular arrhythmias such as atrial fibrillation or atrial flutter. By slowing conduction through the atrioventricular node and suppressing abnormal electrical activity in the heart, atenolol can help restore normal heart rhythm and prevent arrhythmic events.

  5. Reduction of Myocardial Oxygen Demand: By reducing heart rate and myocardial contractility, (S)-(-)-atenolol decreases myocardial oxygen demand, which can be beneficial in individuals with coronary artery disease or ischemic heart disease. Lowering myocardial oxygen demand helps improve oxygen supply-demand balance in the heart and may reduce the frequency and severity of anginal episodes.

  6. Dosage and Administration: (S)-(-)-atenolol is typically administered orally in the form of tablets or capsules. The dosage and frequency of administration may vary depending on the patient's age, weight, medical condition, and response to treatment. It is usually taken once daily, with or without food.

  7. Side Effects: Common side effects of (S)-(-)-atenolol may include fatigue, dizziness, lightheadedness, bradycardia (slow heart rate), hypotension (low blood pressure), cold extremities, gastrointestinal disturbances (e.g., nausea, diarrhea), and worsening of heart failure symptoms in susceptible individuals. These side effects are usually mild and transient but should be reported to a healthcare provider if they persist or worsen over time.

  8. Contraindications: (S)-(-)-atenolol is contraindicated in individuals with known hypersensitivity to beta-blockers, severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated heart failure, and certain other cardiac conditions. It should be used with caution in patients with asthma, chronic obstructive pulmonary disease (COPD), diabetes, peripheral vascular disease, and other comorbidities.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of (s)-(-)-atenolol,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Escherichia coli Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by (s)-(-)-atenolol,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Eggerthella genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Ruminococcus genus Decreases 👪 Source Study
Escherichia genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Enterocloster genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Bifidobacterium genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Coprococcus genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Agathobacter genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Escherichia coli O80:H26 no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Escherichia coli O145 serogroup Decreases 👶 Source Study
Escherichia coli O157 serogroup Decreases 👶 Source Study
Escherichia coli O26 serogroup Decreases 👶 Source Study
Escherichia coli O43 serogroup Decreases 👶 Source Study
Escherichia coli O1:H42 serotype Decreases 👶 Source Study
Escherichia coli O104:H4 serotype Decreases 👶 Source Study
Escherichia coli O121:H19 serotype Decreases 👶 Source Study
Escherichia coli O127:H6 serotype Decreases 👶 Source Study
Escherichia coli O139:H28 serotype Decreases 👶 Source Study
Escherichia coli O157:H7 serotype Decreases 👶 Source Study bloody diarrhea
Escherichia coli O44:H18 serotype Decreases 👶 Source Study
Escherichia coli O55:H7 serotype Decreases 👶 Source Study
Escherichia coli O6:H16 serotype Decreases 👶 Source Study
Escherichia coli O7:K1 serotype Decreases 👶 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Bilophila wadsworthia species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Escherichia coli species Decreases 📓 Source Study Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
Bifidobacterium adolescentis species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Bacteroides caccae species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Slackia sp. NATTS species Decreases ⚗️ Source Study
Coprococcus comes species Decreases 📓 Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Bifidobacterium longum species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of (s)-(-)-atenolol,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.2 0.2
Acne 0.1 -0.1
ADHD 0.7 0.4 0.75
Age-Related Macular Degeneration and Glaucoma 0.3 0.1 2
Allergic Rhinitis (Hay Fever) 0.4 0.4 0
Allergies 1.9 0.7 1.71
Allergy to milk products 0.7 0.3 1.33
Alopecia (Hair Loss) 0.6 0.6
Alzheimer's disease 1.2 1.1 0.09
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 0.5 0.2
Ankylosing spondylitis 1.6 0.3 4.33
Anorexia Nervosa 0.1 0.4 -3
Antiphospholipid syndrome (APS) 0.7 0.2 2.5
Asthma 0.9 0.1 8
Atherosclerosis 0.6 0.1 5
Atrial fibrillation 1.3 0.7 0.86
Autism 3 2.1 0.43
Barrett esophagus cancer 0.2 0.4 -1
benign prostatic hyperplasia 0.2 0.2
Bipolar Disorder 0.7 0.7 0
Brain Trauma 0.4 0.1 3
Cancer (General) 0.7 -0.7
Carcinoma 2.1 1 1.1
Celiac Disease 0.9 1.1 -0.22
Cerebral Palsy 0.6 0.3 1
Chronic Fatigue Syndrome 3.1 2.4 0.29
Chronic Kidney Disease 0.7 0.4 0.75
Chronic Lyme 0.1 -0.1
Chronic Obstructive Pulmonary Disease (COPD) 1.2 0.1 11
Chronic Urticaria (Hives) 1 0 0
Coagulation / Micro clot triggering bacteria 0.9 0.5 0.8
Colorectal Cancer 1 0.4 1.5
Constipation 0.3 0.3
Coronary artery disease 0.5 0.2 1.5
COVID-19 4.5 3.3 0.36
Crohn's Disease 2.5 1.2 1.08
cystic fibrosis 0.5 0.2 1.5
deep vein thrombosis 0.5 0.5 0
Depression 3.8 2.6 0.46
Dermatomyositis 0.4 0.1 3
Eczema 0.3 0.5 -0.67
Endometriosis 1.5 0.3 4
Eosinophilic Esophagitis 0 0.1 0
Epilepsy 1 0.5 1
Fibromyalgia 0.8 0.4 1
Functional constipation / chronic idiopathic constipation 1.1 0.5 1.2
gallstone disease (gsd) 0.9 0.1 8
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.2 0.4 -1
Generalized anxiety disorder 0.5 0.4 0.25
giant cell arteritis 0.1 -0.1
Glioblastoma 0.4 -0.4
Gout 0.1 -0.1
Graves' disease 0.6 0.6 0
Halitosis 0.3 0.4 -0.33
Hashimoto's thyroiditis 0.5 0.4 0.25
Hidradenitis Suppurativa 0.6 0.1 5
Histamine Issues 0.7 0 0
hypercholesterolemia (High Cholesterol) 0.1 0 0
hyperglycemia 0.2 0.3 -0.5
Hyperlipidemia (High Blood Fats) 0.4 0.3 0.33
hypersomnia 0.2 -0.2
hypertension (High Blood Pressure 1.2 1.1 0.09
Hypothyroidism 0.5 -0.5
Hypoxia 0.2 0.2
IgA nephropathy (IgAN) 0.2 -0.2
Inflammatory Bowel Disease 1.8 1.5 0.2
Insomnia 0.5 0.1 4
Intelligence 0.1 0.1
Intracranial aneurysms 0.4 0.3 0.33
Irritable Bowel Syndrome 1.2 0.4 2
Liver Cirrhosis 1.8 1.5 0.2
Long COVID 2.3 2.6 -0.13
Low bone mineral density 0.1 -0.1
Lung Cancer 0.3 0.5 -0.67
Mast Cell Issues / mastitis 0.5 0.3 0.67
ME/CFS with IBS 0.7 0.9 -0.29
ME/CFS without IBS 1.7 1.1 0.55
Menopause 0.3 0.3
Metabolic Syndrome 3.4 1.9 0.79
Mood Disorders 5 2.9 0.72
multiple chemical sensitivity [MCS] 0.5 0.5
Multiple Sclerosis 3.2 1 2.2
Multiple system atrophy (MSA) 0.7 0.2 2.5
neuropathic pain 0.1 -0.1
Neuropathy (all types) 0.4 0.2 1
neuropsychiatric disorders (PANDAS, PANS) 0.3 0.3
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.2 0.8 0.5
NonCeliac Gluten Sensitivity 0.1 -0.1
Obesity 3.2 1.2 1.67
obsessive-compulsive disorder 1.5 0.6 1.5
Osteoarthritis 0.8 0.2 3
Osteoporosis 1 0.1 9
pancreatic cancer 0.4 0.4
Parkinson's Disease 1.8 0.9 1
Polycystic ovary syndrome 0.6 0.5 0.2
Postural orthostatic tachycardia syndrome 0.1 0.2 -1
Premenstrual dysphoric disorder 0.4 0.1 3
primary biliary cholangitis 0.3 0.3 0
Psoriasis 2.3 0.3 6.67
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.9 1.1 1.64
Rosacea 0.2 0.1 1
Schizophrenia 2.2 0.4 4.5
scoliosis 0.1 0.4 -3
Sjögren syndrome 1 0.8 0.25
Sleep Apnea 0.4 0.5 -0.25
Small Intestinal Bacterial Overgrowth (SIBO) 0.7 0.1 6
Stress / posttraumatic stress disorder 1 1.3 -0.3
Systemic Lupus Erythematosus 1.5 0.2 6.5
Tic Disorder 0.2 0.7 -2.5
Tourette syndrome 0 0.1 0
Type 1 Diabetes 0.9 0.7 0.29
Type 2 Diabetes 3.3 1.6 1.06
Ulcerative colitis 1.4 0.7 1
Unhealthy Ageing 1.6 0.2 7

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [34.239.170 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.239.170 ]